ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
AstraZeneca PLC

AstraZeneca PLC (AZN)

78.54
0.36
(0.46%)
Closed May 27 4:00PM
78.54
0.00
(0.00%)
After Hours: 6:08PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
78.54
Bid
44.01
Ask
79.87
Volume
3,566,580
78.08 Day's Range 78.89
0.00 52 Week Range 0.00
Market Cap
Previous Close
78.18
Open
78.13
Last Trade
1
@
78.245
Last Trade Time
Financial Volume
$ 280,266,668
VWAP
78.5813
Average Volume (3m)
-
Shares Outstanding
1,550,163,000
Dividend Yield
-
PE Ratio
32.08
Earnings Per Share (EPS)
3.84
Revenue
45.81B
Net Profit
5.96B

About AstraZeneca PLC

AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put s... AstraZeneca is a global science-led biopharmaceutical company that focuses on the discovery development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive open and collaborative. This approach runs through all that we do. We focus on three main therapy areas Oncology Cardiovascular & Metabolic Disease CVMD and Respiratory and we are also selectively active in the areas of autoimmunity neuroscience and infection. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Cambridge, Gbr
Founded
1970
AstraZeneca PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AZN. The last closing price for AstraZeneca was $78.18. Over the last year, AstraZeneca shares have traded in a share price range of $ 0.00 to $ 0.00.

AstraZeneca currently has 1,550,163,000 shares outstanding. The market capitalization of AstraZeneca is $191.04 billion. AstraZeneca has a price to earnings ratio (PE ratio) of 32.08.

AstraZeneca (AZN) Options Flow Summary

Overall Flow

Bullish

Net Premium

499k

Calls / Puts

600.00%

Buys / Sells

133.33%

OTM / ITM

40.00%

Sweeps Ratio

0.00%

AZN Latest News

Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux

Dans la population globale de l'essai, les résultats de survie ont favorisé numériquement le datopotamab deruxtecan d'AstraZeneca et de Daiichi Sankyo, mais n'ont pas atteint le seuil de...

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

In the overall trial population, survival results numerically favoured AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan but did not reach statistical significance TROPION-Lung01 previously...

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

Additional clinical and real-world data from the industry’s largest and broadest amyloidosis pipeline will advance understanding of underlying mechanisms of disease and unmet needs AstraZeneca...

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

Additional clinical and real-world data from the industry’s largest amyloidosis pipeline will advance understanding of underlying mechanisms of disease and unmet needs AstraZeneca and Alexion...

AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​

Back-to-back plenary presentations from LAURA and ADRIATIC Phase III trials reinforce the potential of TAGRISSO® (osimertinib) and IMFINZI® (durvalumab) in early lung cancer settings​...

アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定

2030年までに20種類の新薬が発売される見通し 既存の腫瘍学、バイオ医薬品、希少疾患のポートフォリオによる大幅な成長 医療の未来を形作り、長期的な成長を促進する破壊的イノベーションへの投資 収益成長と...

AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an

Markteinführung von 20 neuen Medikamenten bis 2030 geplant Signifikantes Wachstum beim Bestandsportfolio in den Bereichen Onkologie, Biopharmazeutika und seltene Krankheiten Investitionen in...

AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030

Lancement prévu de 20 nouveaux médicaments d’ici 2030 Une forte croissance dans les portefeuilles existants de l’oncologie, des produits biopharmaceutiques et des maladies rares Des...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

AZN Discussion

View Posts
IHuser IHuser 2 weeks ago
imo. the whole world read my post and AZN jerked their "vaccine" off of the market....worldwide.


Let's go lawsuits..... * * ***...........let's go lawsuits clap clap clap clap clap!



AZN



IHuser
👍️0
Monksdream Monksdream 4 weeks ago
AZN new 52 week high
👍️0
IHuser IHuser 4 months ago
imo... dirty people play dirty little number tricks see link AZN

https://www.bitchute.com/video/RZXLkuLaJrnz/

IHuser
👍️0
1jas 1jas 9 months ago
anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?
👍️0
1jas 1jas 9 months ago
anyone here see where enzolytics announced yesterday that they have a cure called clone 3 that CURES hiv/aids.?
👍️0
Stockexpertpro Stockexpertpro 11 months ago
lots of Deaths and Fatalities reported This could drop like a rock today heavy float lots of bagholders
👍️0
jondoeuk jondoeuk 11 months ago
Preprint https://www.biorxiv.org/content/10.1101/2023.06.20.545315v1
👍️0
jondoeuk jondoeuk 11 months ago
Next into the clinic should be this https://aacrjournals.org/cancerres/article/83/8_Supplement/LB085/725614/Abstract-LB085-Antitumor-activity-of-AZD0754-a

Also, a trial testing an CLDN18.2-targted version with the same dnTGFbRII armour is planned.

The first TCR-T therapy https://clinicaltrials.gov/ct2/show/NCT05877599 that is armoured as well http://www.neogene.com/staging/wp-content/uploads/2022/04/Keystone-2022-TGFBR2-KO-TP53-R175H-TCR-poster-final-edit.pdf

They have been working on additional edits https://jitc.bmj.com/content/10/Suppl_2/A253
👍️0
BottomBounce BottomBounce 11 months ago
AstraZeneca PLC $AZN Total Debt (mrq) $32.47B
👍️0
MI Dendream MI Dendream 12 months ago
Any idea why the delay for Ultomiris?
👍️0
jondoeuk jondoeuk 1 year ago
The company has inked a non-exclusive licensing deal with Revvity to use its Pin-point base editing platform in the development of new cell therapy treatments for cancer and other immune-mediated diseases. Pin-point uses a novel three-part design with an RNA aptamer guide, a modified Cas9 enzyme and a deaminase enzyme.

The platform is highly efficient and precise, allowing for multiplex editing with >75% editing in each target base. Also, has a strong safety profile with negligible off-target edits and no translocations. In addition, has no impact on cell health and allows for one-step complex engineering, which is simultaneous multiple knock-ins and knockouts (at least seven).
👍️0
jondoeuk jondoeuk 1 year ago
1st foray into CAR-T for $AZN; pres at AACR. GPC3 CAR w/ a dnTGF-B for HCC

Of 5 evaluable at DL1-2. 4/5 uPR (80% uORR). 5/5 tumor reduction; median -31%. Consistent AFP. Not squeaky clean but no DLTs

Promising start - green shoots showing in solid tumor cell therapy recently— Professor Oak (@Prof_Oak_) April 14, 2023
👍️0
ernie44 ernie44 1 year ago
got the wrong stock..... wanted AEZS
👍️0
DarthYoda DarthYoda 1 year ago
"INSIDE PFIZER AND ASTRAZENECA'S UKRAINIAN BIOLAB!":
https://www.bitchute.com/video/3JJO7BdvsDPz/
👍️0
DarthYoda DarthYoda 1 year ago
New PCR Test warning...Sodium Azide..."REMEMBER THE PCR TESTS? WELL THE MSM HAVE CONFIRMED THAT THEY WERE LACED WITH POISONOUS CHEMICAL."

https://www.bitchute.com/video/0zl8fPbSao75/
👍️0
DarthYoda DarthYoda 1 year ago
"THIS IS ABSOLUTELY BRILLIANT… STICKERS OF THE VACCINE INJURED ARE PLACE ON THE BBC HEADQUARTERS, A..":

https://www.bitchute.com/video/f2Y40NiPS6Kq/
👍️0
DarthYoda DarthYoda 1 year ago
"GOVT SCANDALOUSLY MADE IT MANDATORY FOR CARE WORKERS TO BE VACCINATED OR SACKED - WITH NO RISK..."

https://www.bitchute.com/video/Jq0lLY1CXZhn/
👍️0
BottomBounce BottomBounce 1 year ago
$AZN has $31.27 Billion DEBT
👍️0
BottomBounce BottomBounce 1 year ago
$AZN Book Value only $11.35
👍️0
barnyarddog barnyarddog 2 years ago
55.20, the FDA authorized the AstraZeneca drug called Evusheld for adults and children 12 and older whose immune systems haven't responded adequately to COVID-19 vaccines or have a history of severe allergic reactions to the shots. Regulators said the required two antibody injections may be effective at preventing COVID-19 infections for six months.

https://www.clickorlando.com/business/2021/12/08/us-oks-new-covid-19-antibody-drug-for-high-risk-patients/
👍️0
BottomBounce BottomBounce 3 years ago
$AZN Pfizer And AstraZeneca Vaccines Were As Effective As Prior Infection, U.K. Study Finds
👍️0
Tamtam Tamtam 3 years ago
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
👍️0
Tamtam Tamtam 3 years ago
Well, well, well
https://m.republicworld.com/technology-news/social-media-news/facebook-suspends-russian-accounts-running-anti-vaccine-campaign-against-astrazeneca.html
👍️0
Tamtam Tamtam 3 years ago
. U.K. Health secretary warns daily COVID-19 cases could reach 100,000
👍️0
Tamtam Tamtam 3 years ago
. AstraZeneca COVID-19 vaccine is effective against variants identified in India
👍️0
BottomBounce BottomBounce 3 years ago
$AZN EU Ditches AstraZeneca Vaccine. It's Pivoting to Pfizer. --
👍️0
ernie44 ernie44 3 years ago
SEEMS LOW VOLUME ><((((((º>
👍️0
Tamtam Tamtam 3 years ago
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84980530/farxiga-approved-in-the-us-for-the-treatment-of-ch
👍️0
Tamtam Tamtam 3 years ago
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease
👍️0
DCALongRun DCALongRun 3 years ago
Interesting graph on India.

👍️0
BottomBounce BottomBounce 3 years ago
$AZN https://www.fool.com/investing/2021/04/22/pfizer-and-biontech-vaccine-sales-jump-14-billion/
👍️0
ernie44 ernie44 3 years ago
my aptmt is april 8

dont want the AZN jab---its reported Sweden knows something
👍️0
Tamtam Tamtam 3 years ago
“ Emergent’s plant implicated in vaccine mix-up had issues cited by FDA in 2020: AP” is this a joke?
👍️0
ernie44 ernie44 3 years ago
still a problem---AZN vaccine has to be carefully used---and kept cool
👍️0
IHuser IHuser 3 years ago
Reviews leave tbd ^ ^ ^ ^ ________________________AZN
👍️0
I-Man I-Man 3 years ago

BELLUS Health Appoints William Mezzanotte, MD, MPH to its Board of Directors

LAVAL, Quebec—March 24, 2021— BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas.

“Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” commented Dr. Francesco Bellini, Chairman of BELLUS Health. “We are pleased to welcome Bill to our Board of Directors, and we look forward to leveraging his extensive knowledge and guidance to help position BLU-5937 for clinical, regulatory and commercial success.”

Dr. Mezzanotte is currently the Head of Research and Development and Chief Medical Officer at CSL Behring, where he is responsible for developing and executing the Research & Development strategy and portfolio across four continents. Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim. At Boehringer Ingelheim, he oversaw all Global Clinical Development, Medical Affairs, Marketing and Payer activities within the Respiratory portfolio, overseeing the launch of three respiratory products. Previously, Dr. Mezzanotte worked at AstraZeneca for over 15 years, assuming roles of increasing leadership and management responsibility in clinical research and development across multiple therapeutic areas. His last role there was Head of the Inflammation, Neuroscience and Respiratory Global Medicines Unit. Earlier in his career, Dr. Mezzanotte practiced Pulmonary and Critical Care Medicine and ran both a multispecialty sleep disorders center and a pulmonary diagnostics and interventional bronchoscopy laboratory. He received an undergraduate degree from Villanova University and obtained his MD at the University of Pennsylvania and MPH from Johns Hopkins University. Dr. Mezzanotte is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.

“I am excited to join BELLUS’ Board and contribute to the development of the Company’s promising lead candidate, BLU-5937,” said Dr. Mezzanotte. “Patients with refractory chronic cough have no FDA-approved treatments to help alleviate their symptoms. As a highly selective and differentiated P2X3 antagonist, BLU-5937 has the potential to offer meaningful improvement for these patients. I look forward to working with the BELLUS management team and other members of the Board to potentially bring this exciting therapy to the millions of patients that suffer from refractory chronic cough, as well as other hypersensitization-related disorders.”

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.
👍️0
dsscam dsscam 3 years ago
$AZN- true bozos from top to bottom https://www.cnbc.com/2021/03/11/denmark-suspends-use-of-astrazeneca-vaccine-over-reports-of-blood-clots.html
👍️0
Tamtam Tamtam 3 years ago
. AstraZeneca’s COVID-19 shot is said to work against Brazil variant: Reuters
👍️0
Tamtam Tamtam 3 years ago
AstraZeneca’s COVID-19 shots reach Ghana as UN-backed COVAX initiates deliveries

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84421958/astrazeneca-s-covid-19-shots-reach-ghana-as-un-ba
👍️0
Tamtam Tamtam 3 years ago
WHO approves AstraZeneca/Oxford COVID-19 vaccine for emergency use

https://www.reuters.com/article/us-health-coronavirus-who-astrazeneca-idUSKBN2AF1KC
👍️0
Tamtam Tamtam 3 years ago
AstraZeneca Wins WHO Emergency Listing For COVID-19 Vaccine; Street Sees 31% Upside
https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84342162/astrazeneca-wins-who-emergency-listing-for-covid-1
👍️0
Tamtam Tamtam 3 years ago
Serum Institute expects WHO emergency approval for AstraZeneca Covid-19 vaccine Novavax soon

https://www.deccanherald.com/national/serum-institute-expects-who-emergency-approval-for-astrazeneca-covid-19-vaccine-novavax-soon-938986.html
👍️0
Tamtam Tamtam 3 years ago
AstraZeneca has applied for authorization for its Covid-19 vaccine in Europe and the EU pharmaceutical regulator said Tuesday it could give the go-ahead as early as Jan. 29. That´s when the European Medicines Agency´s scientific committee will meet to review analysis of the vaccine´s trial data and, if it recommends authorization, the European Commission could formally authorize AstraZeneca´s vaccine within a few days. If AstraZeneca´s Covid-19 vaccine, which was developed with Oxford University, were authorized for emergency use, it would add at least 300 million doses to the continent´s attempts to limit its deadly winter surge in Covid-19 infections. The EU has preordered 300 million doses with an option for another 100 million, and AstraZeneca has said it will manufacture up to three billion doses of its vaccine this year, which will be crucial in the effort to get doses administered in poorer countries.
👍️0
Tamtam Tamtam 3 years ago
FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease

https://ih.advfn.com/stock-market/NYSE/astrazeneca-AZN/stock-news/84033951/farxiga-granted-priority-review-in-the-us-for-the
👍️0
BottomBounce BottomBounce 3 years ago
$AZN https://www.calcalistech.com/ctech/articles/0,7340,L-3884172,00.html
👍️0
north40000 north40000 3 years ago
MHRA approves use of AZN/Oxford vaccine for use in U.K.
👍️0
Tamtam Tamtam 3 years ago
AstraZeneca’s vaccine formula is 100% effective against severe COVID-19.
https://www.timesofisrael.com/astrazeneca-winning-vaccine-formula-is-100-effective-against-severe-covid-19/
👍️0
Esa Esa 3 years ago
https://www.theguardian.com/world/2020/dec/25/uk-scientists-trial-drug-to-prevent-coronavirus-infection-leading-to-disease

https://news.sky.com/story/covid-19-trials-begin-on-antibody-treatment-that-could-prevent-illness-in-those-recently-exposed-12172623
👍️0
BottomBounce BottomBounce 3 years ago
$AZN Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

https://fool.com/investing/2020/12/16/why-astrazenecas-and-sanofis-bad-news-could-be-gre/
👍️0
speakcheesy speakcheesy 3 years ago
Selling pressure from the arb's driving the stock lower
AstraZeneca $AZN and Alexion $ALXN Factsheet for traders and investors looking to trade the merger arbitrage spread
https://mergerarbitragelimited.com/astrazeneca-azn-and-alexion-alxn-merger/
👍️0

Your Recent History

Delayed Upgrade Clock